title: Obesity Week 2016 Annual Meeting.
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Payal H
authors.initials: PH
authors.lastname: Marathe
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Abigail E
authors.initials: AE
authors.lastname: Dove
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Helen X
authors.initials: HX
authors.lastname: Gao
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Odeh
authors.affiliation: Close Concerns, San Francisco, California, USA.
authors.forename: Kelly L
authors.initials: KL
authors.lastname: Close
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control; D003226:Congresses as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000069450:Liraglutide / Q000627:therapeutic use*; D011236:Prediabetic State / Q000503:physiopathology / Q000517:prevention & control*; D011788:Quality of Life; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D000069450:Liraglutide; C570240:empagliflozin